The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Aclidinium / Formoterol Inhaler (Duaklir Genuair®) has been accepted for use as maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
Levonorgestrel IUD (Jaydess®) has been accepted for use as contraception for up to 3 years.
Tacrolimus prolonged release tablets (Envarsus®) have been accepted for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients. It is noted that this product has demonstrated non-inferiority to a tacrolimus immediate-release capsule and has a similar cost per equivalent dose.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.